Multiple Sclerosis
Multiple sclerosis
... Multiple sclerosis (MS) is a multifocal demyelinating disease with progressive neurodegeneration caused by an autoimmune response to self-antigens in a genetically susceptible ...
10
Pediatric multiple sclerosis: a review
... East Multiple Sclerosis experts dedicated to improving Multiple Sclerosis patient care by translating state-of-the-art science into practical education at local ...
8
The future of multiple sclerosis treatments
... Multiple sclerosis (MS) is a chronic, immune-mediated condition causing inflammation and neurodegeneration in the brain and spinal cord and the most common non-traumatic cause of neurological disability in ...
33
Fatigue Syndrome in Multiple Sclerosis
... symptoms (p value<0.001), and visual symptoms (p value=0.017) was statistically significant. Conclusion: Fatigue is a common compliant in multiple sclerosis. Although, fatigue is a heterogeneous syndrome ...
6
Molecular biomarkers in multiple sclerosis
... Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous system presenting with significant inter- and intraindividual ...
11
Noncoding RNAs in multiple sclerosis
... Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system, is characterized by axonal degeneration and gliosis. Although the causes of MS remain unknown, gene ...
12
Validation of the Persian version of dysphagia in multiple sclerosis questionnaire for the assessment of dysphagia in multiple sclerosis
... Background: About one third of patients with multiple sclerosis (MS) experience dysphagia. Dysphagia can cause complications such as malnutrition, lung infections, aspiration pneumonia and dehydration, thus ...
6
Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre
... for multiple sclerosis; our departments have received financial support for participation in randomised controlled trials of IFNbeta-1b, IFNbeta-1a and copaxone in multiple sclerosis ...
5
Multiple sclerosis
... deterioration. Multiple MRI lesions, particularly those that gadolinium enhance on the first MRI scan, also predict a more severe subsequent ...progressive multiple sclerosis (SPMS) ...
8
Glutathione in multiple sclerosis
... Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), characterised mainly as an autoimmune neurodegenerative disorder that affects the white matter with ...
5
An Atypical Presentation of Multiple Sclerosis
... Multiple Sclerosis (MS) involves an immune mediated process in which an abnormal response of the body’s immune system is directed against the central nervous system ...(CNS). Multiple ...
5
Multiple sclerosis information
... We hope you find the information in this book helpful. If you would like to speak with someone about any aspect of MS, contact the MS Trust information team and they will help find answers to your questions. This book ...
5
Brain atrophy in Multiple Sclerosis
... [44] O. Fernandez, J. C. Alvarez-Cermeno, R. Arroyo-Gonzalez, L. Brieva, M. C. Calles-Hernandez, B. Casanova-Estruch, M. Comabella, V. de las Heras, J. A. Garcia-Merino, M. A. Hernandez-Perez, G. Izquierdo, J. E. ...
10
Future therapies in multiple sclerosis
... remitting multiple sclerosis (RRMS) and the second is a combination study involving induction with oral cladribine and maintenance therapy with interferon ß-1a 44µg given thrice ...
5
The role of microglia in multiple sclerosis
... Abstract: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). Microglia are the resident innate immune cells in the CNS; they play an important role in the processes of ...
7
The use of natalizumab for multiple sclerosis
... randomly assigned to receive natalizumab 300 mg intra- venously every 4 weeks or placebo infusion. At 1 year, the primary outcome was annualized relapse rate (ARR), and at 2 years, the primary outcome was the cumulative ...
12
Alemtuzumab in the treatment of multiple sclerosis
... Abstract: Alemtuzumab (formerly known as Campath-1H) has recently been approved by the European Medicines Agency for highly-active, relapsing-remitting multiple sclerosis (MS). The molecule targets the CD52 ...
9
Sleep Abnormalities in Multiple Sclerosis
... Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative demyelinating disease of the central nervous system defined by a wide range of symptoms and signs that disrupt physical, cognitive, ...
17
Vitamin D and multiple sclerosis.
... Multiple sclerosis (MS) is a chronic demyelinating disease and also is one of the most common disabling neurological disorders in young and middle-aged ...
6
Natalizumab in the treatment of multiple sclerosis
... therapies within the last 3 months. These requirements aim to reduce the risk of developing PML and to catch potential cases of PML as early as possible. Nonetheless, until more is known about additional risk factors, ...
10